Clinical Trials for Leukemia

While you don’t need a doctor’s referral to participate in a clinical trial, it is strongly recommended that you speak with your provider about the potential benefits and risks. Clinical trials have guidelines (eligibility criteria) that tell providers who can participate. These criteria are outlined in the trial listings and include information like age, sex, the type and stage of cancer, treatment history, medications, and other medical conditions. Each trial has its own guidelines. In order to participate in a clinical trial, you will be evaluated by the medical staff conducting the study to determine whether you meet the trial’s inclusion criteria.

201401085

A phase 1/2 study of cytokine-induced memory-like NK cells in patients with AML or MDS Phase I/II Principal Investigator Cashen, Amanda Disease Site Myeloid and Monocytic Leukemia; Other Hematopoietic Learn more about this study at:…

201402042

A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome Phase…

201510167

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment Phase II/III Principal Investigator Jacoby, Meagan Disease Site Other…

201605064

A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR RELAPSED OR REFRACTORY HIGHER-RISK MYELODYSPLASTIC SYNDROMES Phase I Principal Investigator…

201606003

Improving risk assessment of AML with a precision genomic strategy to assess mutation clearance Phase II Principal Investigator Jacoby, Meagan Disease Site Myeloid and Monocytic Leukemia Learn more about this study at: clinicaltrials.gov

201606146

A Phase IIa Study of BL-8040 in Combination with Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Phase II Principal Investigator Uy, Geoffrey Disease Site Lymphoid Leukemia Learn more about this study at:…

201608007

A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients with Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype Phase III Principal…

201609087

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement Phase II (Cancer Control) Principal Investigator Oh, Stephen Disease Site Lymphoid Leukemia;…

201610088

A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation Phase II Principal Investigator Cashen, Amanda Disease Site Myeloid and Monocytic Leukemia Learn more about this study…

201612068

Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) Phase III…

201612148

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia Phase III Principal Investigator Abboud, Camille Disease…

201701084

A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) with Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Phase II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study…

201706011

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physicians Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts

201708159

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden…

201709041

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML after Allogeneic Hematopoietic Cell Transplant in Children and Adults Phase I/II Principal Investigator Cashen, Amanda Disease Site Myeloid and Monocytic Leukemia Learn more about this…

201709068

A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation Phase I Principal Investigator Pusic, Iskra Disease Site Other Hematopoietic Learn more about this study at: clinicaltrials.gov

201710050

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission Phase III…

201712157

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39) with Newly Diagnosed Precursor B-Cell ALL Phase III…

201802152

Pevonedistat in Combination with Ruxolitinib for Treatment of Patients with Myelofibrosis Phase I Principal Investigator Oh, Stephen Disease Site Other Hematopoietic Learn more about this study at: clinicaltrials.gov

201805175

An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant Phase N/A (Cancer Control) Principal Investigator Dipersio, John Disease Site Other Hematopoietic Learn more about this…

201807045

A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis Phase II Principal Investigator Schroeder, Mark Disease Site Other Hematopoietic Learn more about this study…

201807178

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment…

201808163

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia Phase III Principal Investigator Uy, Geoffrey Disease Site Myeloid and…

201808202

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Phase III Principal Investigator Vij, Ravi…

201809141

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within one year…

201810124

A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) Phase I Principal Investigator Schroeder, Mark Disease Site Multiple Myeloma Learn more about this study at:…

201901003

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen) Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study…

201901148

A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease Phase II Principal Investigator Uy, Geoffrey…

201902007

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy Phase II/III Principal Investigator Uy, Geoffrey Disease Site Myeloid and Monocytic Leukemia Learn…

201902041

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) Phase III Principal Investigator Bartlett, Nancy…

201903114

A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome after T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase I Principal Investigator…

201903210

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib…

201904056

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D) Phase N/A Principal Investigator Westervelt, Peter Disease Site Hodgkin’s Lymphoma; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin’s Lymphoma; Other Hematopoietic Learn more about this study…

201905012

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about…

201905082

A Phase Ib Study of AZD6738 for Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy Phase I (Cancer Control) Principal Investigator Jacoby, Meagan Disease Site Chronic Myeloid Leukemia (CML); Myelodysplastic Syndrome…

201906041

A Phase 1b Study of SEL120 in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase I Principal Investigator Abboud, Camille Disease Site Myeloid and Monocytic Leukemia; Other Hematopoietic Learn more about this study…

201906131

A Phase 1 b trial of CPX-351 Lower Intensity Therapy (LIT) plus Venetoclax as First Line Treatment for Subjects with AML who are Unfit for Intensive Chemotherapy Phase I (Cancer Control) Principal Investigator Uy, Geoffrey…

201907148

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma Phase II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn…

201907150

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) Phase III…

201909142

Prognostic Significance of Serial Molecular Annotation in Secondary Acute Myeloid Leukemia (sAML) in patients treated with CPX-351 Phase N/A Principal Investigator Jacoby, Meagan Disease Site Myeloid and Monocytic Leukemia

201910006

A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF EQ001 IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT VERSUS HOST DISEASE Phase I/II Principal Investigator Schroeder, Mark Disease Site Other…

201910101

A Multi-Center Phase 2 Study of Combined Modality Treatment with Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS Phase II Principal Investigator Schroeder, Mark Disease Site Acute Myeloid Leukemia (AML);…

201910168

A phase I study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in multiple myeloma patients following autologous stem cell transplant in the front-line setting. Phase I/II (Cancer Control) Principal Investigator Vij,…

201910194

A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201910200

Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma Phase II Principal Investigator Schroeder, Mark Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201911012

A Single-Arm, Open-Label, Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease after Peripheral Blood Hematopoietic Cell Transplantation Phase I Principal Investigator Schroeder, Mark Disease Site Hodgkin’s Lymphoma; Lymphoid…

201911061

A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207) Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201911131

A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients Phase I Principal Investigator Xiang, Zhifu Disease Site Hodgkin’s Lymphoma; Lymphoid Leukemia; Myeloid and…

201911163

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Phase III Principal Investigator Stockerl-Goldstein, Keith Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201912013

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation Phase I/II Principal Investigator Dipersio, John Disease…

201912015

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy Phase…

201912077

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant…

201912136

A Phase Ib, open-label, dose-escalation study to evaluate the safety and pharmacokinetics of UTTR1147a in combination with standard of care in patients undergoing allogeneic hematopoietic stem cell transplantation Phase I (Cancer Control) Principal Investigator Pusic,…

202001061

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and…

202002074

AN EXPLORATORY PHASE 1B OPEN-LABEL MULTIARM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CC-90009 IN COMBINATION WITH ANTI-LEUKEMIA AGENTS IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA Phase I Principal Investigator Uy, Geoffrey Disease Site Myeloid…

202003066

Evaluation of Vigamox Treatment for Ocular Graft-Versus-Host Disease Phase II Principal Investigator Margolis, Todd Disease Site Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Chronic Lymphocytic Leukemia (CLL); Chronic Myeloid Leukemia (CML); Leukemia, other; Lymphoid…

202003159

A Study of Front Line Ibrutinib for Newly Diagnosed Chronic Graft-versus-Host Disease Phase II Principal Investigator Pusic, Iskra Disease Site Leukemia, other; Lymphoid Leukemia; Multiple Myeloma; Other Hematopoietic Learn more about this study at: clinicaltrials.gov

202004253

AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA Phase I/II Principal…

202005075

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard…

202005165

Phase II Trial with Safety Lead-in of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Phase II Principal Investigator Cashen, Amanda Disease Site Non-Hodgkin’s Lymphoma Learn more about this study…

202005167

A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders Phase I/II Principal Investigator Oh, Stephen Disease Site Other Hematopoietic…

202006109

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage…

202006110

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage…

202007059

Composite Health Assessment Model for Older Adults: Applying Pretransplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation Phase N/A Principal Investigator Pusic, Iskra Disease Site Hodgkin’s Lymphoma; Leukemia, other; Lymphoid Leukemia;…

202007143

Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis Phase II (Cancer Control) Principal Investigator Oh, Stephen Disease Site Other…

202007148

ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome Phase III (Cancer Control) Principal Investigator Abboud, Camille Disease Site Other…

202008047

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants…

202008120

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia Phase III Principal Investigator Oh, Stephen…

202008197

A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients Phase III (Cancer Control) Principal Investigator Oh, Stephen Disease Site Other Hematopoietic Learn more…

202009027

A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma Phase I Principal Investigator Stockerl-Goldstein, Keith Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

202009085

BLockade of PD-1 Added to Standard Therapy to target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab (VAP) Versus Venetoclax and…

202009151

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies Phase I (Cancer Control) Principal…

202011117

Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogenic Hematopoietic Cell Transplantation Recipients Phase I/II Principal Investigator Dubberke, Erik Disease Site Other Hematopoietic Learn more about this study at: clinicaltrials.gov

202011122

A Phase 2 Trial Evaluating the Efficacy of Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Phase II Principal Investigator Christopher, Matthew Disease Site Myeloid and…

202012040

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma…

202103086

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (auto-HCT) for Multiple Myeloma (MM) Phase II Principal Investigator Stockerl-Goldstein, Keith Disease Site Multiple…

202103090

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about…